Justice Ketanji Brown Jackson, a Biden appointee who has spent much of the current term on the losing side of major cases, authored a unanimous Supreme Court decision Thursday that clarified the legal standard for patent disputes involving generic drugs. All nine justices, including the Court's six conservatives, joined her opinion in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
The 9-0 ruling reversed the U.S. Court of Appeals for the Federal Circuit and sent the case back for further proceedings. At its core, the dispute turns on when brand-name drugmakers can accuse generic competitors of encouraging patent infringement through the use of so-called "skinny labels", a practice that affects how lower-cost medicines reach American consumers.
The decision matters for two reasons. First, it touches the pocketbooks of millions of Americans who rely on generic prescriptions. Second, it offers a useful reminder that the Supreme Court is not always the partisan theater its critics make it out to be, even when a liberal justice holds the pen.
The drug at the center of the dispute is Vascepa, first approved in 2012 to treat severe hypertriglyceridemia. It later gained approval for reducing cardiovascular risk in a much larger group of patients. Amarin, the maker of Vascepa, holds patents related to that broader cardiovascular use.
Hikma Pharmaceuticals sought to market a generic version of Vascepa while carving out the patented cardiovascular use from its label. That practice, selling a generic drug with a label that omits certain patented uses, is what the pharmaceutical world calls a "skinny label." It is a feature of the Hatch-Waxman Act, the federal statute that governs competition between brand-name and generic drugs.
Amarin sued, alleging that Hikma's marketing amounted to inducing doctors to prescribe the generic for the patented use. A federal district court dismissed the case. The Federal Circuit reversed that dismissal, finding the allegations plausible enough to proceed.
The Supreme Court stepped in to settle the question of what legal standard governs these claims, specifically, what it takes to show that a generic drugmaker engaged in what Jackson's opinion called "active encouragement" of patent infringement.
Unanimous decisions at the Supreme Court draw less attention than the bitter 5-4 or 6-3 splits that dominate cable news. But they reveal something about how the justices actually work when a legal question is narrow enough to cut across ideological lines.
For Jackson, the opinion is her second unanimous ruling this term. Earlier this year, she authored the 9-0 decision in Urias-Orellana v. Bondi, an immigration case that required federal appeals courts to defer to immigration judges' findings when reviewing asylum claims. That outcome, a liberal justice writing an opinion that tightened the standard for asylum seekers, drew attention precisely because it defied easy partisan categorization.
The Court has handed down several other lopsided decisions this term. In a separate case, the justices backed the FCC's $100 million fines against Verizon and AT&T in an 8-1 ruling, another instance where the expected ideological battle lines failed to materialize.
The Hikma ruling arrives during a term in which Jackson has been the justice most often on the losing side. Supreme Court term statistics show she was in the majority in about 72 percent of cases during the 2024-25 term, the lowest rate of any justice on the bench.
That number tells a story. The Court's conservative majority has controlled the docket, and Jackson has frequently found herself in dissent. Just last week, in Fernandez v. United States, she issued a lone dissent in an 8-1 ruling centered on whether prisoners can use compassionate release to challenge their convictions. In that case, she broke not only from the conservatives but from her fellow liberal justices, Elena Kagan and Sonia Sotomayor.
A lone dissent against eight colleagues, including the two justices most ideologically aligned with her, is not something a justice does to score political points. It suggests Jackson is willing to follow her own reading of the law even when it isolates her completely. Whether one agrees with her conclusions or not, that kind of independence is worth noting.
Conservative frustration with the Court has surfaced in other recent cases. Justice Clarence Thomas, for instance, sharply rebuked the Court for taking up a convicted murderer's death penalty appeal, reflecting a broader unease on the right about the institution's willingness to revisit settled criminal cases.
The practical stakes of the Hikma decision extend well beyond the two companies involved. Generic drugs account for the vast majority of prescriptions filled in the United States. A 2026 analysis published in the medical journal JAMA described timely competition from generic drugs as "the single most important mechanism for lowering prescription drug spending in the U.S."
The "skinny label" system exists precisely to balance two competing interests: protecting pharmaceutical patents and getting affordable alternatives to patients. When a generic drugmaker carves out patented uses from its label, it is supposed to be able to sell the drug for non-patented uses without fear of an infringement lawsuit. The question is what happens when a brand-name company alleges the generic maker is quietly encouraging doctors to prescribe the drug for the patented use anyway.
By clarifying the legal standard for those claims, the Court's decision will shape how aggressively brand-name companies can use patent litigation to slow generic competition. If the standard is too loose, brand-name firms can tie up generic competitors in court for years. If it is too strict, genuine infringement goes unchecked.
The Court did not resolve the underlying dispute. It reversed the Federal Circuit's approach and sent the case back for further proceedings under the clarified framework. Lower courts will now have to evaluate Amarin's specific claims against Hikma under the new standard.
Democrats have spent years arguing that the Supreme Court is a broken, hyper-partisan body in need of structural reform. Some have laid the groundwork for expanding the number of justices, a move Republicans have rightly resisted as a naked power grab designed to dilute the conservative majority.
Cases like Hikma complicate that narrative. When all nine justices, appointed by presidents of both parties, spanning a wide ideological range, agree on the correct reading of a statute, it is hard to maintain that the institution is simply a rubber stamp for one side's agenda.
That does not mean every decision will be unanimous, nor should it be. The justices disagree on genuinely hard questions. But the reflexive progressive claim that the Court's conservative majority is lawless or illegitimate looks thinner every time a Biden appointee writes an opinion that six conservative justices sign without hesitation.
The Court has also drawn attention this term for cases it declined to hear. It refused to take up Florida's challenge to states issuing commercial driver's licenses to illegal immigrants, a decision that frustrated conservatives who wanted the justices to weigh in on a matter with clear public safety implications.
And in criminal law, the Court sidestepped IQ standards in an Alabama death penalty case, drawing a sharp dissent and raising questions about whether the justices are too cautious in certain areas where clarity is needed.
The Hikma case now returns to the lower courts, where the parties will litigate under the legal framework the Supreme Court has established. The outcome will determine whether Amarin can proceed with its infringement claims against Hikma's generic version of Vascepa, and, more broadly, how much room generic drugmakers have to operate under the skinny-label system.
For patients and taxpayers, the downstream effects could be significant. Every month a generic drug is delayed by patent litigation is a month consumers pay brand-name prices. The Court's clarification of the "active encouragement" standard should, in theory, bring more predictability to these disputes and reduce the kind of drawn-out litigation that keeps cheaper drugs off pharmacy shelves.
Whether the lower courts apply the new standard faithfully remains to be seen. But the Supreme Court has spoken, all nine of them, together, and that alone is worth something in a term that has produced no shortage of division.
When the law is clear enough for a Biden appointee and six conservative justices to agree without a single separate opinion, maybe the system is working better than the people who want to blow it up would have you believe.
